-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech's IM1240 shows anti-tumor activity in treatment-resistant cancer models in preclinical study

PUBT·11/20/2026 14:03:18
Listen to the news
Purple Biotech's IM1240 shows anti-tumor activity in treatment-resistant cancer models in preclinical study
  • Purple Biotech presented preclinical IM1240 results at the EORTC-NCI-AACR Symposium in Barcelona on November 20, 2026.
  • The antibody demonstrated tumor-killing activity in patient-derived lung, head and neck, and bladder cancers resistant to immunotherapy.
  • Blocking the NKG2A immune checkpoint improved tumor killing beyond T-cell engagement alone.
  • Its capped design reduced systemic cytokine release and prolonged exposure in nonhuman primates compared with an uncapped variant.
  • The findings support advancing IM1240 toward clinical testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200900PRIMZONEFULLFEED9881453) on November 20, 2026, and is solely responsible for the information contained therein.